Deals in Depth: March 2009
Our monthly overview of dealmaking in the biopharmaceutical, medical device and in vitro diagnostics industries. March 2009 dealmaking highlights: BMS' worldwide ex-Japanese license to Nissan/Teijin's CV candidate NTC801 topped the alliance list in terms of potential deal value at $210mm. The remaining pharma alliances for March didn't even surpass $50mm in pre-commercial value. In M&As, the Big Pharma mega merger of Merck and Schering-Plough was the biggest news, in a deal valued around $42bn. Pharmaceutical financings were down by about $100mm compared with February, and Early VC rounds made up the majority of the $406mm raised. Funding for device firms, on the other hand, was up from last month to $297mm thanks to a strong showing of late venture financings.
You may also be interested in...
Scanwell Health, a leader in smartphone-enabled home diagnostics tests, has announced a partnership with Beckton Dickson.
908 Devices, Zimmer Biomet and Ortho Clinical Diagnostics have all appointed new directors, Biolase promotes executive vice president to chief executive officer role, and more.
The Swedish liquid biopsy start-up expects to be the first company to secure US FDA approval for a metabolism-based urine test for the early detection of kidney cancer in post-surgery patients.